Listing 3 - Actual negotiations

Indication:

Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima))

Indication:

Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima)

Indication:

Advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with imatinib, sunitinib, and regorafenib

Indication:

Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy

Indication:

Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation (in combination with pembrolizumab)

Indication:

Advanced or metastatic renal cell carcinoma (RCC) with no prior systemic therapy for metastatic renal cell carcinoma (RCC), in adult patients (In combination with pembrolizumab)

Indication:

Acute Graft-Versus-Host disease

Indication:

Chronic Graft-versus-host Disease

Indication:

Excessive daytime sleepiness or cataplexy in adult patients with narcolepsy

Indication:

Diabetic Macular Edema